Medical Devices Startups

Neural Dynamics Technologies develops neural interface technology aimed at advancing neuroscience research and treating neurological diseases. The company brings together neuroscientists, engineers, and clinicians in an interdisciplinary approach.

1 investor

Neuralert develops a patented algorithm and wearable technology aimed at early stroke detection. The company operates in the medical device and digital health space, with ties to University of Pennsylvania neurology research.

1 investor

eNeura develops single-pulse transcranial magnetic stimulation (sTMS) neuromodulation devices for the acute and preventive treatment of migraine. Its products are used by patients, including veterans through the VA, and prescribed by healthcare providers, with operations in the US and UK.

1 investor

Neurent Medical develops the NEUROMARK system, a radiofrequency ablation device that targets hyperactive autonomic nerves to treat chronic rhinitis symptoms in ENT patients. The company focuses on advancing neuromodulation technology to provide durable symptom relief and improve respiratory health outcomes.

1 investor

Neurent Medical develops a minimally invasive radiofrequency ablation system to treat chronic rhinitis by disrupting hyperactive autonomic nerves in the nasal passages. The company serves otolaryngology (ENT) physicians and patients seeking relief from chronic inflammatory sino-nasal diseases.

1 investor

Neurescue develops a medical device that treats cardiac arrest patients by inserting a balloon-occlusion device through the femoral artery to increase blood flow to the heart and brain during chest compressions. The device targets patients ineligible for defibrillation and uses automated pressure-limited inflation to improve resuscitation outcomes.

1 investor

Neurobell develops AI-powered medical technology for continuous monitoring of neonatal brain activity in neonatal intensive care units. The company combines clinical expertise with machine learning to advance neonatal brain monitoring capabilities.

1 investor

Neurochase provides consultancy to biotech and pharmaceutical companies on directly delivering therapies to the central nervous system, drawing on experience with catheter infusions and convection-enhanced delivery. It supports preclinical study protocols, toxicology, surgical workflow and training, and is developing its own CED drug-delivery devices.

1 investor

NeuroDex develops blood-based biomarkers and diagnostic assays for neurological diseases, including rare genetic disorders, Parkinson's disease, Alzheimer's disease, and ALS. The company works with biopharmaceutical companies to enable patient selection, treatment monitoring, and accelerated disease diagnosis in clinical development programs.

1 investor

NeuroEquilibrium operates a network of clinics specializing in diagnosis and treatment of vertigo, dizziness, and balance disorders through a deep-tech platform that integrates cloud technology, computer vision, and remote diagnostics. The company serves patients and healthcare providers in India and globally, aiming to standardize care for vestibular disorders.

1 investor

Neurofit is a web-based cognitive rehabilitation platform that enables clinicians to assign adaptive cognitive activities, track client performance data, and generate clinical reports for insurance claims. It serves occupational therapists, speech-language pathologists, neuropsychologists, and rehabilitation medicine professionals treating clients across the lifespan.

1 investor

Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.

1 investor

NeuroGenesis develops cell therapies for neurodegenerative diseases, leveraging its NG CELL platform to enhance stem cells for treating conditions like multiple sclerosis and ALS. The company is advancing Phase IIb clinical trials in Europe and Israel with a focus on remyelinating and regenerative cellular medicine.

1 investor

NeuroKaire uses cellular modeling and biological measurement to help mental health providers and patients make treatment decisions for depression based on measurable biological response rather than trial-and-error approaches. The company offers diagnostic testing through CLIA-certified laboratories to provide earlier biological context for antidepressant selection.

1 investor

Neurolens makes therapeutic eyeglass lenses with patented Contoured Prism technology and a measurement device that customizes prescriptions to reduce symptoms of eye misalignment such as headaches, neck pain, motion sickness, and eye strain. It serves eye-care patients across all ages through providers, offering Single Vision, Office, and Progressive lens designs.

1 investor

Neurolieve is a life-science company developing therapeutics for neuropathic and chronic pain, with expertise in neuroscience, clinical pain medicine and drug development. Its lead program, NLV-01, is built on protein-engineering technology contributed by co-founding partner LifeArc.

1 investor

Neuromod is a medical technology company that developed Lenire, an FDA-approved bimodal neuromodulation device for treating tinnitus. Its device is available through clinics across Europe and the United States and has been studied in large-scale clinical trials.

1 investor

Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.

1 investor

NeurOptics develops pupillometry technologies for clinical decision-making in critical care, neurology, neurosurgery, and emergency medicine. The company serves medical professionals and clinical researchers globally.

1 investor

NeuroSigma is a bioelectronic medical device company that makes non-invasive external trigeminal-nerve stimulation systems to treat chronic neurological and neuropsychiatric disorders. Its Monarch eTNS System is an FDA-cleared, prescription home-use device for treating pediatric ADHD in children ages 7 to 12, with additional programs targeting conditions such as autism spectrum disorder, epilepsy, and depression.</parameter> <parameter name="founders">[]

1 investor

Neurosom develops a wearable sleep therapy device called Sleep WISP that uses EEG monitoring and AI-driven electrical stimulation to improve deep sleep and reduce dementia risk. The system is designed for at-home use and targets patients seeking cognitive health and disease prevention.

1 investor

Axoneurotech develops neural engineering technology using a biology-first approach at the intersection of biology and engineering.

1 investor

NeuroTx develops AI-powered electroceutical and neurotechnology solutions that use neural decoding and non-invasive vagus nerve stimulation to support sleep quality, cognitive function, and metabolic health. The company integrates wearable devices, mobile applications, and machine learning to deliver personalized bio-signal-based interventions for consumers and patients.

1 investor

NeuroVigil develops portable, single-channel EEG brain-monitoring technology and analysis software for neurological research, disease diagnosis, and pharmaceutical clinical trials. Its systems are used to monitor sleep and brain activity for conditions such as ALS, Alzheimer's, and Parkinson's, serving researchers, drug developers, and patients.

1 investor